Online inquiry

IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8236MR)

This product GTTS-WQ8236MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8236MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3637MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ10220MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ12732MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ12894MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ11246MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ16004MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ9132MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ8816MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IBI-308
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW